Scroll down to exit
Lung cancer is a major cause of global morbidity and mortality with approximately 1.6 million deaths globally each year. Although a global epidemic, it is unclear what makes one individual over another more susceptible to developing lung cancer. Johnson & Johnson (China) Investment Ltd. and Johnson & Johnson Innovation LLC are committed to flipping the script on lung cancer. How do we eliminate lung cancer by leveraging the totality of science and technology to prevent, intercept and cure lung cancer?
The goal of this QuickFire Challenge is to employ response to stressors in order to evaluate immune and gastrointestinal health and ultimately predict risk of IBD. If you have an idea for a product, technology, or methodology to investigate the response of the human immune and gastrointestinal systems to stressors, Janssen Research & Development is awarding up to $50,000 with possible mentorship opportunities to help make that idea a reality.